ROS1 and lung adenocarcinoma: However, a case series study reported prolonged PFS with pemetrexed as first-line and maintenance therapy in patients with ROS1-driven lung adenocarcinoma [10], indicating that patients in this subgroup may be optimal candidates for pemetrexed chemotherapy.